BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (the BIO-FLARE study): protocol for a non-randomised longitudinal cohort study.
DMARD cessation
DMARD withdrawal
Flare
Pathogenesis
Remission
Rheumatoid arthritis
Journal
BMC rheumatology
ISSN: 2520-1026
Titre abrégé: BMC Rheumatol
Pays: England
ID NLM: 101738571
Informations de publication
Date de publication:
19 Jul 2021
19 Jul 2021
Historique:
received:
10
03
2021
accepted:
09
04
2021
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
20
7
2021
Statut:
epublish
Résumé
Our knowledge of immune-mediated inflammatory disease (IMID) aetiology and pathogenesis has improved greatly over recent years, however, very little is known of the factors that trigger disease relapses (flares), converting diseases from inactive to active states. Focussing on rheumatoid arthritis (RA), the challenge that we will address is why IMIDs remit and relapse. Extrapolating from pathogenetic factors involved in disease initiation, new episodes of inflammation could be triggered by recurrent systemic immune dysregulation or locally by factors within the joint, either of which could be endorsed by overarching epigenetic factors or changes in systemic or localised metabolism. The BIO-FLARE study is a non-randomised longitudinal cohort study that aims to enrol 150 patients with RA in remission on a stable dose of non-biologic disease-modifying anti-rheumatic drugs (DMARDs), who consent to discontinue treatment. Participants stop their DMARDs at time 0 and are offered an optional ultrasound-guided synovial biopsy. They are studied intensively, with blood sampling and clinical evaluation at weeks 0, 2, 5, 8, 12 and 24. It is anticipated that 50% of participants will have a disease flare, whilst 50% remain in drug-free remission for the study duration (24 weeks). Flaring participants undergo an ultrasound-guided synovial biopsy before reinstatement of previous treatment. Blood samples will be used to investigate immune cell subsets, their activation status and their cytokine profile, autoantibody profiles and epigenetic profiles. Synovial biopsies will be examined to profile cell lineages and subtypes present at flare. Blood, urine and synovium will be examined to determine metabolic profiles. Taking into account all generated data, multivariate statistical techniques will be employed to develop a model to predict impending flare in RA, highlighting therapeutic pathways and informative biomarkers. Despite initial recruitment to time and target, the SARS-CoV-2 pandemic has impacted significantly, and a decision was taken to close recruitment at 118 participants with complete data. This study aims to investigate the pathogenesis of flare in rheumatoid arthritis, which is a significant knowledge gap in our understanding, addressing a major unmet patient need. The study was retrospectively registered on 27/06/2019 in the ISRCTN registry 16371380 .
Sections du résumé
BACKGROUND
BACKGROUND
Our knowledge of immune-mediated inflammatory disease (IMID) aetiology and pathogenesis has improved greatly over recent years, however, very little is known of the factors that trigger disease relapses (flares), converting diseases from inactive to active states. Focussing on rheumatoid arthritis (RA), the challenge that we will address is why IMIDs remit and relapse. Extrapolating from pathogenetic factors involved in disease initiation, new episodes of inflammation could be triggered by recurrent systemic immune dysregulation or locally by factors within the joint, either of which could be endorsed by overarching epigenetic factors or changes in systemic or localised metabolism.
METHODS
METHODS
The BIO-FLARE study is a non-randomised longitudinal cohort study that aims to enrol 150 patients with RA in remission on a stable dose of non-biologic disease-modifying anti-rheumatic drugs (DMARDs), who consent to discontinue treatment. Participants stop their DMARDs at time 0 and are offered an optional ultrasound-guided synovial biopsy. They are studied intensively, with blood sampling and clinical evaluation at weeks 0, 2, 5, 8, 12 and 24. It is anticipated that 50% of participants will have a disease flare, whilst 50% remain in drug-free remission for the study duration (24 weeks). Flaring participants undergo an ultrasound-guided synovial biopsy before reinstatement of previous treatment. Blood samples will be used to investigate immune cell subsets, their activation status and their cytokine profile, autoantibody profiles and epigenetic profiles. Synovial biopsies will be examined to profile cell lineages and subtypes present at flare. Blood, urine and synovium will be examined to determine metabolic profiles. Taking into account all generated data, multivariate statistical techniques will be employed to develop a model to predict impending flare in RA, highlighting therapeutic pathways and informative biomarkers. Despite initial recruitment to time and target, the SARS-CoV-2 pandemic has impacted significantly, and a decision was taken to close recruitment at 118 participants with complete data.
DISCUSSION
CONCLUSIONS
This study aims to investigate the pathogenesis of flare in rheumatoid arthritis, which is a significant knowledge gap in our understanding, addressing a major unmet patient need.
TRIAL REGISTRATION
BACKGROUND
The study was retrospectively registered on 27/06/2019 in the ISRCTN registry 16371380 .
Identifiants
pubmed: 34275488
doi: 10.1186/s41927-021-00194-3
pii: 10.1186/s41927-021-00194-3
pmc: PMC8286860
doi:
Types de publication
Journal Article
Langues
eng
Pagination
22Subventions
Organisme : Medical Research Council
ID : MR/P020941/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N026977/1
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
Nat Med. 2020 Aug;26(8):1295-1306
pubmed: 32601335
N Engl J Med. 2011 Dec 8;365(23):2205-19
pubmed: 22150039
J Autoimmun. 2019 Dec;105:102298
pubmed: 31280933
J Transl Med. 2018 Jan 29;16(1):18
pubmed: 29378619
Arthritis Rheum. 2013 Jun;65(6):1448-56
pubmed: 23460124
Ann Rheum Dis. 2011 Feb;70(2):315-9
pubmed: 21068104
Sci Rep. 2018 May 9;8(1):7370
pubmed: 29743579
BMC Rheumatol. 2019 Jun 13;3:2
pubmed: 31225429
Ann Rheum Dis. 2017 Dec;76(12):2105-2112
pubmed: 28847766
Ann Rheum Dis. 2015 Jun;74(6):1132-7
pubmed: 25143522
J Allergy Clin Immunol. 2018 Jan;141(1):445-448.e4
pubmed: 28987811
Lancet. 1996 Feb 10;347(8998):347-52
pubmed: 8598699
Nat Rev Immunol. 2017 Jan;17(1):60-75
pubmed: 27916980
Nat Rev Rheumatol. 2016 Sep;12(9):532-42
pubmed: 27411910
Ann Rheum Dis. 2016 Jan;75(1):45-51
pubmed: 25660991
RMD Open. 2017 Jan 30;3(1):e000382
pubmed: 28255449
Lancet. 2010 Sep 25;376(9746):1094-108
pubmed: 20870100
Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25
pubmed: 26545825
RMD Open. 2018 Oct 26;4(2):e000799
pubmed: 30488001
Rheumatology (Oxford). 2012 Dec;51 Suppl 6:vi28-36
pubmed: 23221584
Nat Rev Immunol. 2010 Aug;10(8):605-11
pubmed: 20651747
Ann Rheum Dis. 2016 Feb;75(2):466-73
pubmed: 25649145
Clin Rheumatol. 2018 May;37(5):1189-1197
pubmed: 29388086
Ann Rheum Dis. 2014 Mar;73(3):492-509
pubmed: 24161836